Clinical implications of the tiotropium/olodaterol inhaler for patients with chronic obstructive pulmonary disease

References

• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2017 report. 2017 [cited 2017 Oct 12]. Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/
   Google Scholar
• GBD. Disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1545–1602.
   PubMed Web of Science ®Google Scholar
• GBD. Mortality and causes of death collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1459–1544.
   PubMed Web of Science ®Google Scholar
• Molimard M, Colthorpe P. Inhaler devices for chronic obstructive pulmonary disease: insights from patients and healthcare practitioners. J Aerosol Med Pulm Drug Deliv. 2015;28:219–228.
   PubMed Web of Science ®Google Scholar
• Dekhuijzen PNR, Lavorini F, Usmani OS. Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat® or HandiHaler®. Patient Prefer Adherence. 2016;10:1561–1572.
   PubMed Web of Science ®Google Scholar
• Hanada S, Wada S, Ohno T, et al. Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch. Int J Chron Obstruct Pulmon Dis. 2015;10:69–77.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Niewoehner D, Brooks J, et al. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res. 2014;15:78.
   PubMed Web of Science ®Google Scholar
• Derom E, Brusselle GG, Joos GF. Efficacy of tiotropium–olodaterol fixed-dose combination in COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:3163–3177.
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Ghafouri M, Dai L, et al. COPD patient satisfaction with ipratropium bromide/albuterol delivered via Respimat: a randomized, controlled study. Int J Chron Obstruct Pulmon Dis. 2013;8:139–150.
   PubMed Web of Science ®Google Scholar
• Sulaiman I, Cushen B, Greene G, et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195:1333–1343.
   PubMed Web of Science ®Google Scholar
• Sanchis J, Gich I, Pedersen S. on behalf of the aerosol drug management improvement team (ADMIT). Systematic review of errors in inhaler use. Has patient technique improved over time? Chest. 2016;150:394–406.
   PubMed Web of Science ®Google Scholar
• Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105:930–938.
   PubMed Web of Science ®Google Scholar
• Anderson P. Use of Respimat® Soft Mist™ inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis. 2006;1:251–259.
   PubMedGoogle Scholar
• Dalby RN, Eicher J, Zierenberg B. Development of Respimat® Soft Mist™ inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl.). 2011;4:145–155.
   PubMedGoogle Scholar
• Haidl P, Heindl S, Siemon K, et al. Inhalation device requirements for patients’ inhalation maneuvers. Respir Med. 2016;118:65–75.
   PubMed Web of Science ®Google Scholar
• Dal Negro RW. Dry powder inhalers and the right things to remember: a concept review. Multidiscip Respir Med. 2015;10:13.
   PubMed Web of Science ®Google Scholar
• Azouz W, Chetcuti P, Hosker HS, et al. The inhalation characteristics of patients when they use different dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2015;28:35–42.
   PubMed Web of Science ®Google Scholar
• Hoppentocht M, Hagedoorn P, Frijlink HW, et al. Technological and practical challenges of dry powder inhalers and formulations. Adv Drug Deliv Rev. 2014;75:18–31.
   PubMed Web of Science ®Google Scholar
• Morikawa M, Kanemitsu Y, Tsukamoto H, et al. A case of anaphylaxis in the pediatric patient with milk allergy due to traces of milk protein in the lactose used as an excipient of inavir inhalation. Arerugi. 2016;65:200–205.
   PubMedGoogle Scholar
• Robles J, Motheral L. Hypersensitivity reaction after inhalation of a lactose-containing dry powder inhaler. J Pediatr Pharmacol Ther. 2014;19:206–211.
   PubMedGoogle Scholar
• Dalby R, Spallek M, Voshaar T. A review of the development of Respimat® Soft Mist™ inhaler. Int J Pharm. 2004;283:1–9.
   PubMed Web of Science ®Google Scholar
• Dhand R. Aerosol plumes: slow and steady wins the race. J Aerosol Med. 2005;18:261–263.
   PubMedGoogle Scholar
• Hochrainer D, Hölz H, Kreher C, et al. Comparison of the aerosol velocity and spray duration of Respimat® Soft Mist™ inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005;18:273–282.
   PubMedGoogle Scholar
• Ciciliani A-M, Wachtel H, Heussel CP, et al. Evaluation of Respimat® Soft Mist™ inhaler based on in vitro measurements and CFD simulations. Respir Drug Deliv Eur. 2015;2:357–362.
   Google Scholar
• Newman SP, Steed KP, Reader SJ, et al. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J Pharm Sci. 1996;85:960–964.
   PubMed Web of Science ®Google Scholar
• Newman SP, Brown J, Steed KP, et al. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest. 1998;113:957–963.
   PubMed Web of Science ®Google Scholar
• Brand P, Hederer B, Austen G, et al. Higher lung deposition with Respimat® Soft Mist™ inhaler than HFA-MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis. 2008;3:763–770.
   PubMedGoogle Scholar
• Hodder R, Price D. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat® Soft Mist™ inhaler. Int J Chron Obstruct Pulmon Dis. 2009;4:381–390.
   PubMedGoogle Scholar
• Chrystyn H, Small M, Milligan G, et al. Impact of patients’ satisfaction with their inhalers on treatment compliance and health status in COPD. Respir Med. 2014;108:358–365.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64:939–943.
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Povero M. Acceptability and preference of three inhalation devices assessed by the handling questionnaire in asthma and COPD patients. Multidiscip Respir Med. 2016;11:7.
   PubMed Web of Science ®Google Scholar
• Schürmann W, Schmidtmann S, Moroni P, et al. Mist™ inhaler versus hydrofluoroalkane metered dose inhaler: patient preference and satisfaction. Treat Respir Med. 2005;4:53–61.
   PubMedGoogle Scholar
• Boehringer Ingelheim International GmbH. STIOLTO™ RESPIMAT® (tiotropium bromide and olodaterol) inhalation spray, for oral inhalation use. 2015 [cited 2017 Jun 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206756s002lbl.pdf
   Google Scholar
• Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J. 2015;45:969–979.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Rogliani P, Matera MG, et al. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016;149:1181–1196.
   PubMed Web of Science ®Google Scholar
• Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109:1312–1319.
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Karpel J, Bennett N, et al. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies. NPJ Prim Care Respir Med. 2017;27:7.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Casaburi R, Frith P, et al. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD. Eur Respir J. 2017;49:1601348.
   PubMed Web of Science ®Google Scholar
• Sauer R, Hänsel M, Buhl R, et al. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study. Int J Chron Obstruct Pulmon Dis. 2016;11:891–898.
   PubMed Web of Science ®Google Scholar
• Troosters T, Maltais F, Leidy N, et al. Effect of bronchodilation and exercise training with behavior modification on exercise tolerance and downstream effects on symptoms and physical activity in COPD. Am J Respir Crit Care Med. 2018 Apr 17. [Epub ahead of print].
   PubMedGoogle Scholar
• Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369:1491–1501.
   PubMed Web of Science ®Google Scholar